Synapse - Ferrata Storti Foundation

Results (357)

A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma

Meeting Abstract

Palomba, M. L.; Till, B. G.; Park, S. I.; Morschhauser, F.; Cartron, G.; Marks, R.; Penuel, E.; Chitra, S.; Byon, J. C. H.; Popplewell, L.
Haematologica (2016)

Fulltext@MSK | Save

High hemoglobin concentrations and risk of thrombosis: Causality or confounding?

Meeting Abstract

Rognvaldsson, S.; Lund, S. H.; Hultcrantz, M.; Eiriksdottir, G.; Harris, T. B.; Gudnason, V.; Kristinsson, S. Y.
Haematologica (2016)

Fulltext@MSK | Save

Integrative genomics identifies the molecular basis of resistance to Azacitidine therapy in Myelodysplastic Syndromes

Meeting Abstract

Unnikrishnan, A.; Papaemmanuil, E.; Beck, D.; Verma, A.; Kumari, A.; Woll, P.; Richards, L.; Knezevic, K.; Chandrakanthan, V.; Thoms, J.; more...
Haematologica (2016)

Fulltext@MSK | Save

Increased risk of second malignancies in patients with myeloproliferative neoplasms diagnosed in Sweden 1973-2009. A population-based cohort study of 9,379 patients

Meeting Abstract

Landtblom, A. R.; Bower, H.; Andersson, T. M. L.; Dickman, P. W.; Bjorkholm, M.; Kristinsson, S. Y.; Hultcrantz, M.
Haematologica (2016)

Fulltext@MSK | Save

Safety study of crenolanib, a Type I FLT3 inhibitor, with cytarabine/daunorubicin or cytarabine/idarubicin induction and high-dose cytarabine consolidation in newly diagnosed FLT3+ AML

Meeting Abstract

Wang, E.; Stone, R.; Tallman, M.; Thompson, J.; Ontiveros, E.; Olson, G.; Galinsky, I.; Pond, B.; Uchida, A.; Urity, V.; more...
Haematologica (2016)

Fulltext@MSK | Save

Clinical response in relapsed/refractory AML patients correlates with leukemic blast mobilization and differentiation induced by BL-8040, a potent CXCR4 antagonist; Results of a phase IIA study